Tech Company Financing Transactions
Ajax Therapeutics Funding Round
EcoR1 Capital Management, Boxer Capital and Memorial Sloan Kettering Cancer Center participated in a $40 million venture round for Ajax Therapeutics. The round was announced by the company on 6/2/2021.
Transaction Overview
Company Name
Announced On
6/2/2021
Transaction Type
Venture Equity
Amount
$40,000,000
Round
Undisclosed
Investors
EcoR1 Capital Management (Lead Investor) (Scott Platshon)
Proceeds Purpose
Proceeds from the financing will support the advancement of Ajax' lead drug development programs targeting hematologic malignancies.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
275 Madison Ave. 39th floor
New York, NY 10016
USA
New York, NY 10016
USA
Phone
Website
Email Address
Overview
Advances in molecular genetics and biology have led to the development of new classes of targeted therapies for the treatment of hematologic malignancies. However, many of these therapies, while selective for a particular drug target, often interact with other related proteins which can limit their efficacy and lead to unwanted side effects.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Martin Vogelbaum
VP - R & D
Craig Masse
Browse more venture capital transactions:
Prev: 6/2/2021: Electric Era venture capital transaction
Next: 6/2/2021: Notal Vision venture capital transaction
Share this article
Where The Data Comes From
We report on every notable VC transaction. All VC database entries on this site come from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs